Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples